Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 21

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 21
---
The
Small Business Innovation Research or SBIR, program, as developed by Congress under the Small Business Innovation Development Act of
1982, is designed to encourage domestic small businesses to engage in Federal Research/Research and Development (“R/R&D”)
that has the potential for commercialization. Through a competitive awards-based program, SBIR enables small businesses to explore their
technological potential and provides the incentive to profit from its commercialization. Some of the SBIR’s program goals include
stimulating technological innovation, meeting Federal research and development needs and encouraging participation in innovation and
entrepreneurship.

16

The
SBIR program is a three-phase program. Phase 1 is to establish the technical merit and commercial potential of the proposed R/R&D
efforts. Phase 2 is to continue the R/R&D efforts initiated in Phase 1 and funding is based on the results achieved in Phase 1. Phase
3 allows for the small business to pursue commercialization objectives resulting from the Phase 1 and 2 R/R&D activities. In addition,
companies that have successfully completed Phases I and II are also eligible to apply for Phase IIb funding.

In
addition to the SBIR contract to fund our Phase I clinical study on Ropidoxuridine in combination with RT for treatment of advanced gastrointestinal
cancers, we have also received awards of SBIR contracts from the NIH to address prostate cancer health disparities and prostate cancer
radiation biomarker development.

As
of the date of this Annual Report, all SBIR contracts received by the Company have been completed. The Company submitted a final report
for SBIR contract #75N81018C00031 on March 28, 2022. The following summary of terms for the three Phase II SBIR contracts is provided
below.

Summary
of SBIR Contracts

    ●
    SBIR
    contract #261201400013C: Phase I ($191,971) and Phase II ($1,428,117) for Clinical Development of IPdR for Radiosensitization, dates
    September 19, 2014 through August 3, 2017. Subcontract to Brown University/LifeSpan Rhode Island Hospital. No related intellectual
    property.

    ●
    SBIR
    contracts # HHSN261201600038C; Phase I ($224,687) and #261201800016C: Cell-Based Models for Prostate Cancer Health Disparity Research
    - Moonshot Project (Phase